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Abstract 
Increased levels of plasma oxLDL, which is the oxidized fraction of Low Density Lipoprotein (LDL), are associated with atherosclerosis, an 
inflammatory disease, and the subsequent development of severe cardiovascular diseases that are today a major cause of death in 
modern countries. It is therefore important to find a reliable and fast assay to determine oxLDL in serum. A new immunosensor 
employing three monoclonal antibodies (mAbs) against oxLDL is proposed in this work as a quick and effective way to monitor oxLDL. 
The oxLDL was first employed to produce anti-oxLDL monoclonal antibodies by hybridoma cells that were previously obtained. The 
immunosensor was set-up by self- assembling cysteamine (Cyst) on a gold (Au) layer (4 mm diameter) of a disposable screen-printed 
electrode. Three mAbs were allowed to react with N-hydroxysuccinimide (NHS) and ethyl(dimethylaminopropyl)carbodiimide (EDAC), and 
subsequently incubated in the Au/Cys. Albumin from bovine serum (BSA) was immobilized further to ensure that other molecules apart 
from oxLDL could not bind to the electrode surface. All steps were followed by various characterization techniques such as 
electrochemical impedance spectroscopy (EIS) and square wave voltammetry (SWV). The analytical operation of the immunosensor was 
obtained by incubating the sensing layer of the device in oxLDL for 15 minutes, prior to EIS and SWV. This was done by using standard 
oxLDL solutions prepared in foetal calf serum, in order to simulate patient's plasma with circulating oxLDL. A sensitive response was 
observed from 0.5 to 18.0 mg mL-1. The device was successfully applied to determine the oxLDL fraction in real serum, without prior 
dilution or necessary chemical treatment. The use of multiple monoclonal antibodies on a biosensing platform seemed to be a successful 
approach to produce a specific response towards a complex multi-analyte target, correlating well with the level of oxLDL within 
atherosclerosis disease, in a simple, fast and cheap way. 
 
1. Introduction 
Coronary heart disease is the result of inadequate circulation of 
blood in the myocardium and occurs when the coronary arteries 
become partially blocked or obstructed.1 Atherosclerosis is the 
main cause of cardiovascular disease and it is an 
in ammatory condition characterized by thickening and 
hardening of the arterial wall, with the deposition of fatty 
substances, choles- terol, cellular waste products and other 
substances, leading to plaque formation, called atheroma, and 
causing hemodynamic alteration.2,3 Furthermore, an 
atheroma, in later stages, can totally or partially block 
blood ow through the arteries and 
 
cause plaque rupture with haemorrhage and development of 
thrombosis, which are the main causes of morbidity and 
mortality in westernized countries, leading to a considerable 
economic overload.3–5 
LDL is the main carrier of cholesterol in the blood and exerts 
important physiological and cellular function and regulation of 
metabolic pathways. However, a large amount of clinical 
evidence, as well as epidemiological studies, correlate high 
concentrations of plasma cholesterol and increased risk of 
cardiovascular disease.6 Furthermore, increased plasma levels 
of LDL, especially its oxidized form (oxLDL), are associated with 
atherosclerosis. oxLDL promotes vascular dysfunction by 
exerting direct cytotoxicity towards endothelial cells and 
increases chemotactic properties for monocytes and macro- 
phages and consequent transformation into foam cells, which 
contribute to atherogenesis.7–10 
Although the oxLDL level in circulating plasma is commonly 
recognized as an important predictive marker of risk of 
cardiovascular events, simple and cheap assays for oxLDL level 
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determination remain to be developed. There are many ways to 
determine oxLDL in the blood by ELISA (enzyme-linked 
immunosorbent assay) methods, such as employing different 
monoclonal and polyclonal antibodies that are capable of 
detecting oxLDL fractions involved in the atherogenesis.11–13 
Alternative methods employ anti-oxLDL Abs conjugated to gold 
nanoparticles and subsequent detection by liquid chromatog- 
raphy/tandem-mass spectrometry (LC-MS/MS)13 or proteohe- 
paran sulfate coated hydrophobic silica for subsequent 
ellipsometry readings.14–16 These two approaches are however 
unsuitable for applications in point-of-care diagnosis, also 
being coupled to expensive equipment. 
Despite the differences observed between different ELISA 
procedures used for oxLDL determination, which are directly 
correlated with the biological and clinical signi cance of oxLDL 
measures,11 the gold standard methods to determine oxLDL are 
still carried out using commercial ELISA kits. These methods 
are also very expensive and time consuming, requiring highly 
quali ed personnel and special handling procedures/storage 
conditions. Therefore, novel approaches with a simple proce- 
dure and low cost are highly necessary and would be greatly 
appreciated. 
Biosensors could offer advantageous features compared to 
diagnostic tools like ELISA, due to their sensitivity, selectivity, 
simplicity, speed, low-cost, portability, and automation feasi- 
bility.17–23 An easy approach towards biosensing design in this 
context is to include an antibody as a biological recognition 
element, usually recognized as an immunosensor. 
Although immunosensors display several attractive features, 
there are two major difficulties hindering the performance of 
immunosensing devices. One difficulty is to ensure that the 
Fragment antigen-binding (Fab) is suitably exposed for antigen 
binding. Many studies report random binding of Abs, preventing 
many of the Fab fragments in the receptor platform from 
binding to the antigen. To solve this problem, several authors 
reported complex chemical systems driving the Abs connected to 
the solid support in a speci c orientation,24–28 but in this case the 
many reactions involved turn this a very complex process. Also, 
the effectiveness of each stage of chemical modi cation condi- 
tioning such an orientation is unknown, for which this process 
may not be as effective as expected in the theoretical approach. 
The other major difficulty is to obtain a speci c response 
towards the antigen. The use of monoclonal antibodies (mAb) 
may turn out to be a successful approach to obtain such a 
speci c response towards a selected target antigen.28–31 This is 
particularly relevant when the analyte is not a single structure 
but a mixture of several/complex target compounds. This is the 
case for oxLDL, obtained by random oxidation of native LDL. 
Thus, this work proposes the development of an immuno- 
sensor for oxLDL by employing simple chemistry strategies that 
ensure suitable orientation of the mAb on top of a gold sensing 
layer of screen-printed electrodes (SPEs). Furthermore, three 
different mAbs were merged in the same platform to ensure 
speci c antigen binding towards a target of multiple chemical 
structures. The optimization of the sensor design, the subse- 
quent analytical performance and its real application are pre- 
sented further. 
2. Materials and methods 
All procedures involving animals or humans were approved and 
conducted according to the Institutional Ethics Committee on 
research involving human (CEPSH of ICB/USP) (Protocol no. 
1033/CEP) and the Committee for Animal Care and Utilization 
(CEUA of ICB/USP) (Protocol no. 116; book 02; page 119). 
 
2.1     Equipment 
The electrochemical measurements were conducted in a 
potentiostat/galvanostat from Metrohm Autolab/PGSTAT302N, 
impedimetic module and controlled by NOVA so ware. Au-SPEs 
were purchased from DROPSENS (DRP-C220AT), consisting of 
working and counter electrodes made of gold and the reference 
electrode and electrical contacts made of silver. The diameter of 
the working electrode was 4 mm. The SWV measurement was 
conducted in 5.0 mmol L-1 of [Fe(CN)6]
3- and 5.0 mmol L-1 of 
[Fe(CN)6]
4-,  prepared  in  PBS  pH  7.  In  SWV  potentials  were 
changed from -0.7 to +0.7 V, corresponding to a frequency of 50 
Hz and a step height of 150 mV. EIS assays were conducted with 
the same redox couple [Fe(CN)6]
3-/4- at a standard potential of 
0.12 V, using a sinusoidal potential perturbation with an 
amplitude of 0.01 V (RMS) and the number of frequencies equal 
to 50, logarithmically distributed over a frequency range of 0.1– 
100 kHz. The impedance data were tted to a Randles equiva- 
lent circuit using the implemented NOVA so ware. 
 
2.2    LDL isolation 
Blood samples were collected from healthy volunteers of both 
sexes, a er fasting for 12 hours, with cholesterol and triglyc- 
eride concentrations in plasma within the normal range 
(cholesterol <240 mg dL-1 and triglycerides <160 mg dL-1, as 
con rmed by laboratorial data). Blood was collected in blood 
collection vacuum tubes (BD Vacutainer), containing 0.054 mL 
of anticoagulant, ethylenediaminetetraacetic acid (EDTA, diso- 
dium salt), 4.5 mL volume for suction. The blood of each 
volunteer was separately centrifuged (1000 x g, 4 oC,   
10 minutes) and was used to create a pool of plasma. Then, a 
mixture of preservatives with 2 mM benzamidine, 0.5% genta- 
mycin, 0.25% chloramphenicol, 0.5 mM phenyl- 
methylsulfonyl uoride (PMSF) and 0.1 units per mL aprotinin 
was added to this pool. 
LDL (d ¼ 1006 ± 1063 g mL-1) was isolated by sequential 
ultracentrifugation at 100 000g for 20 h at 4 oC,32 using a 50Ti 
rotor, L-8 Ultracentrifuge, Beckman (VLDL: 12 h, density 
1.006 g mL-1; LDL: 20 h, density < 1.063 g mL-1; HDL: 40 h, 
density < 1.21 g mL-1). LDL was dialyzed for 48 h in PBS–EDTA 
0.01% pH 7.4 (0.9% NaCl, 0.3% Na2HPO4, 0.2% H2PO4; NaOH 
0.38% and 0.01% EDTA) and ltered (0.22 mm in diameter, 
Millipore). LDL preparations were stored at 4 oC. The protein 
content was measured by Lowry's method.33 
 
2.3 LDL oxidation 
For the preparation of oxLDL, native LDL from 4 to 6 mg mL-1 
was incubated with a solution of copper sulphate (CuSO4), at a 
  
 
nal concentration of 20 mM for 18 h at 37 oC. The reaction was 
blocked with the addition of 1 mM EDTA (Fernvik et al., 2004; 
Zaratin et al., 2002). To assess the extent of the LDL oxidation, 
the malondialdehyde (MDA) content was analyzed by 
measuring the thiobarbituric acid reactive substances 
(TBARSs).34,35 MDA was formed as a consequence of the perox- 
idation of LDL particles. 
 
2.4 Monoclonal antibodies (mAbs) 
The mAb-producing hybridomas anti-oxLDL, previously 
obtained inside the group, were tested against the product of 
oxLDL oxidation separated by molecular exclusion chromatog- 
raphy (superdex 200), by an ELISA indirect method and by 
competitive ELISA with synthetic peptides of apoB.36 The 
hybridomas were cultured in Dulbecco's Modi ed Eagle's 
Medium (DMEM) (Sigma-Aldrich) containing 10% foetal calf 
serum (FCS), 100 mg mL-1  L-glutamine and 50 mg mL-1 genta- 
micin. The isotypes of the monoclonal antibodies (73, 77 and 87), 
present in supernatant uid of hybridoma cultures, were stored 
at -20 oC until puri cation. 
The isotypes of the mAbs were determined by an ELISA 
indirect method, using the kit of Mouse Monoclonal Antibody 
Isotyping Reagents (SIGMA, Saint Louis, Missouri, USA). Brie y, 
the ELISA procedure was conducted with the anti-mouse IgG1, 
IgG2a, IgG2b, IgG3, IgM or IgA produced in goat, used at diluted 
1 : 1000 to coat the wells of microtiter plates and le  overnight at 
4 oC. Non-speci c reactions were blocked with skim milk (5% w/ 
v in PBS; Molico Milk, Nestle) for 2 hours at 37 oC. A er that, the 
mAb73, 77 or 87 were added at a concentration of 250 mg mL-1 
and le  for 1 hour at 37 oC. Then, anti-mouse Ig horseradish 
peroxidase linked whole Ab (Amersham LIFE SCIENCE) diluted 
1 : 1000 were added into every well and kept for 1 hour at 37 oC. 
This was followed by the addition of o-phenylenediamine dihy- 
drochloride (OPD) (Sigma-Aldrich) with hydrogen peroxide as a 
substrate. Between all steps, the plate was washed four times 
with PBS–Tween containing 0.05% Tween 20 (PBS-SM-T20) and 
three times with PBS. The reaction was stopped with sulphuric 
acid 2 N and read using a spectrophotometer at 492 nm. 
 
2.5 Antibody puri cation 
The mAbs in the supernatant uid were puri ed by affinity 
chromatography using Protein G (Protein G Sepharose 4 Fast 
Flow-Sigma-Aldrich). For this, 2 mL of Protein G were added to 
each 500 mL of hybridoma supernatant uid, and the resulting 
mixture was subjected to mild agitation for rv6 hours, to allow 
the antibodies to bind to Protein G. A er stirring, the ask was 
allowed to stand for the precipitation of Protein G. The super- 
natant was removed and Protein G was washed with PBS until 
the solution stayed clear. The non-adsorbed proteins were 
removed by washing with PBS. The mAbs were eluted from the 
column with 0.5 M acetic acid, and collected in 10 drops of 
eluent ow, every 5 seconds, in tubes containing 250 mL of Tris 
1 M of pH 8.8, per well (to neutralize pH of the samples). The 
presence of proteins (antibodies) in each tube was detected by 
the Bradford method. A er this, the aliquots were gathered to 
create a pool with a higher amount of protein, and subsequently 
dialyzed in PBS for 18 h. The samples were stored at 4 oC, 
protected from light. The as-puri ed mAbs were assayed for 
protein content by Lowry's method,33 separated in smaller vials, 
and stored at -20 oC until use. 
2.6 Building of the immunosensor 
The immunosensor was setup by self-assembling Cyst (Cyste- 
amine (C9H13N3O5) 50 mM) for 1 hour on the working 4 mm f 
gold (Au) layer of a SPE. Antibodies were le  to react with NHS 
(N-hydroxysuccinimide (C4H5NO3) 25 mM) and EDAC (N-(3- 
dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride) for 
15 minutes, and subsequently incubated in the Au/Cys. A drop 
of BSA (0.5 mg mL-1) was then added to the sensing layer, for 
1 hour, to avoid non-speci c binding. The modi ed elctrodes were 
nally incubated with oxLDL in buffer solution  for 
15 minutes. All these steps of chemical modi cation were 
followed by EIS and SWV. 
 
2.7.    Optimization of the immunosensor 
The kind and amount of mAbs were tested rst. Biosensors were 
prepared with single mAb (73, 77 or 87) or multiple mAbs (73, 77 
and 87 in the same device). The concentration of mAbs was 
always 50 mg mL-1 (in single mAb and in the pool of 3 different 
species of mAbs). Overall, the biosensor with a single mAb and 
three mAbs were produced with the same concentration of Ab. 
The obtained biosensors were calibrated by adding succes- 
sive oxLDL standard solutions of increasing concentrations, 
and using the same conditions of electrical operation afore- 
mentioned for EIS and SWV studies. 
The selectivity of the biosensor was assessed for native LDL, 
myoglobin equine skeletal muscle (Sigma-Aldrich) and hae- 
moglobin human (Sigma-Aldrich), solutions prepared in PBS 
pH 7, with high concentrations of 100 mg mL-1, for all negative 
controls. The time of contact given to these solutions was 
1 hour. 
To simulate the use of the immunosensor with patient's 
plasma with circulating oxLDL, the lowest concentration of 
oxLDL tested was diluted in FCS and the response was checked 
by EIS and SWV. 
All electrochemical tests were carried out in triplicate. 
 
3. Results and discussion 
3.1. Oxidation of native LDL 
To measure the extent of LDL oxidation, thiobarbituric acid 
measurements were employed. This compound is an important 
indicator of lipid peroxidation. Its concentration increased with 
the incubation time of LDL in copper sulphate, up to a 
maximum value where the oxidation no longer proceeded. The 
best time for oxidation was found at an 18 h incubation period. 
The isolation and puri cation of the oxLDL in solution was 
made by ionic chromatography. As in any oxidation, carboxylic 
functions were introduced by oxidation and these carry an 
anionic charge under physiological pH. So, the oxLDL fraction 
a er an 18 h oxidation period was retained longer than the 
native LDL in an ion exchange column (Resource Q). 
  
 
3.2. Antibody–antigen  interactions 
All tests made regarding the mAbs showed that these were 
isotyped as IgG1. The mAb was tested against the product 
of oxLDL separated by molecular exclusion chromatog- 
raphy (superdex 200) by ELISA method.36 By competitive 
ELISA with synthetic peptides of apoB, only the mAb77 
showed slightly decreased binding to oxLDL. Further 
information regarding these antibodies has been pre- 
sented by Freitas, 2004.36  
The size distribution pro le of oxLDL and the size of 
formation of the antigen (oxLDL)–antibody (mAb anti-oxLDL) 
complex was determined by dynamic light scattering. This was 
done simply by placing a drop of the solutions under study in 
Avid Nano DLS equipment. 
The oxLDL solutions displayed nanostructures with an 
average size of 67.7 nm f, with a standard deviation of 65.6 nm. 
This unusually high standard deviation was expected, because 
the oxidized nanostructures were produced by random oxida- 
tion of the native LDL.37 The expected average molecular weight 
of oxLDL was 85 013.13 kDa, corresponding to a polydispersion 
% of 0.94. 
The antigen–antibody (Ag–Ab) complex had an average size 
of 208.9 nm f, with a standard deviation of 130.1 nm. Consid- 
ering that each mAb may bind to two Ag species, and that the 
variation in the size of Ag was 65.6 nm, a variation in 130.1 nm 
of the Ag–Ab complex demonstrated the great ability of the Ab to 
bind to the target structures, independent of their size or exact 
structure. This was also expected because the mAbs had been 
targeted for this oxLDL mixture. The expected average molec- 
ular weight of oxLDL was 440 162.20 kDa, corresponding to a 
polydispersion% of 0.39. 
 
 
3.3. Immunosensor design 
The immunosensor design consisted of creating an amine 
monolayer on a gold support to bind to the Ab through its Fc 
terminal. This would allow both paratope regions of the Ab to be 
free for subsequent antigen binding. The overall process can be 
seen in Fig. 1. 
The amine monolayer was created by incubating the gold 
support on cysteamine: the thiol group bound to the gold and 
led to the formation of a compact amine monolayer (Fig. 1A). 
The presence of this layer on gold could be con rmed by the 
increase in the charge-transfer resistance (Rct) observed a er 
the gold clean support was incubated in cysteamine (Fig. 2). The 
Rct corresponded to the diameter of the semicircle, and its 
increase corresponded to an increased resistance in the electron 
 
 
Fig. 2 The EIS response of the immunosensor assembly with single 
mAb (A) mAb73, (B) mAb77 and (C) mAb87. 
 
 
 
Fig. 1 Immunosensor assembly. A gold electrode with self-assembled cysteamine (A); antibody binding (B); BSA binding (C) and the modified 
electrodes were finally incubated with oxLDL (D). 
  
 
transfer kinetics of the iron redox-probe, accounting for the 
formation of a resistive layer. 
In order to ensure an extensive Ab binding to the amine 
surface under mild conditions, the –COOH groups of the Ab had 
to be activated rst by conventional EDAC–NHS chemistry.38 
Once activated, the antibodies were connected to the support by 
covalent amide functional groups (Fig. 1B), promoting a 
signi cant increase in the Rct of the Au/NH2 support (Fig. 2). 
This behaviour was consistent for all mAbs used. 
All regions of the Au/NH2/mAb support different from par- 
atope sites could allow binding of other chemical species 
besides oxLDL. To avoid this, the biomaterial was incubated in 
BSA (Fig. 1C). Again, a signi cant increase in Rct was observed 
(Fig. 2), thus con rming that BSA was bound to the Au/amine/ 
mAb surface and indicating that a great number of non-speci c 
response sites had been blocked. 
The Ag present in the immunosensor was expected to bind to 
the paratope sites of the Ab (Fig. 1D). As oxLDL particles were 
mainly negatively charged, the subsequent Rct should decrease, 
considering that the iron redox probe used to check the charge 
transfer capability had the same charge. This was observed for 
all immunosensors (Fig. 2). 
 
3.4. Single and poly-monoclonal antibody response 
Different mAbs obtained from the same oxLDL mixture were 
called mAb73, mAb77 and mAb87. Each is expected to have 
 
 
Fig. 3 EIS spectra obtained on the assembly of the multi-mAb 
immunosensor ((A) including a cleaned Au surface, Cys, mAb73, 77 and 
87 together (mAb), block with BSA and the response to the first 
standard of oxLDL, 5 mg mL-1) and its subsequent calibration with 
oxLDL ranging from 5 to 30 mg mL-1 (B). 
different epitopes for the complex targeted mixture, meaning    
that immunosensors assembled with individual or combined 
mAb mixtures could have different electrical operation. 
The immunosensor was rst assembled in a single Ab 
arrangement, immobilizing only mAb73 or mAb77 or mAb87 on 
the Cys layer of the Au-SPE. Overall, each of these displayed 
similar EIS spectra, responding well to the oxLDL antigen 
diluted in buffer solution (Fig. 2). The EIS spectra of the 
assembly of the biosensor with multi-mAbs (the three kinds 
together in a single SPE) are shown in Fig. 3A. Its analytical 
performance (Fig. 3B) was similar to that displayed by the single 
mAb SPEs, which is in clear agreement with the simple fact that 
the area of the working layer to which the Ab may bind is the 
same, independent of the number or kind of Ab binding to it. 
The as-obtained device showed a linear response from 5 to 20 mg 
mL-1, with slope and intercept values of 41.33 (U x mL mg-1) 
and 1267.4 U, respectively. Each device was produced in tripli- 
cate and the results obtained showed good reproducibility, 
always below 5%. 
Overall, the single or multi-immunosensing devices dis- 
played similar features. Still, only multi-mAb was used in 
further studies, because it was reasonable to assume that 
different epitopes for the same target mixture comprising 
multiple oxidised nanostructures of LDL would favour the 
speci city of the analytical response. 
 
3.5. Selectivity study 
To check the ability of the mAb to discriminate oxLDL nano- 
structures from the parent or coexisting compounds in serum, 
the response of the multi-mAb biosensor was checked against 
native LDL, myoglobin and haemoglobin. This was done by 
placing a drop of the corresponding solutions on the platform 
that had been blocked by BSA. This study was made with foreign 
solutions having a high concentration of the target species, 
100 mg mL-1, and the time given for affinity reaction with the 
platform was 1 hour. This procedure was the same for the 
negative control made with buffer. Repeated applications of 
solutions with foreign species were made, ensuring that the 
effects of their abnormally high levels in serum would also be 
checked. 
In general, the immunosensor incubated in foreign species 
showed the same response as that shown by the immunosensor 
a er BSA incubation (Fig. 4), con rming that they were unable to 
react with the mAbs placed in the outer surface of the 
biosensor. None of the previous foreign species at any of the 
concentrations tested were able to change the baseline response 
of the immunosensor. Even native LDL was unable to change 
the response of the device, thus con rming the speci city of 
the dimensional platform towards the targeted oxLDL material. 
The biosensor did not respond to other antigens at 15 minutes 
and even for contact times up to 1 h. 
Overall, the biosensor demonstrated excellent results in 
terms of sensitivity and speci city. Tests with nonspeci c 
antigens as native LDL, myoglobin and hemoglobin, made with 
FCS without human oxLDL, also grant avoiding or masking the 
response of the device with monoclonal antibodies. The results 
showed the feasibility of the immunosensor to be applied to 
patients with an over concentration of side-antigens. 
  
 
 
 
Fig. 4 Selectivity test against proteins in serum that coexist with 
oxLDL. (A) myoglobin, (B) native LDL and (C) haemoglobin. 
 
 
3.6     Analytical performance 
The immunosensor with multi-mAbs was assembled next to 
check its response against oxLDL, for concentrations up to 
50 mg mL-1. The overall response showed that the biosensor 
responded well a er 5 mg mL-1 oxLDL, this being the concen- 
tration level included in the linear response range of the device. 
The linear response was observed  up to 20 mg mL-1,  being 
expressed as Rct (U) ¼ 41.33 x oxLDL (mg mL
-1) + 1267.4, with a 
squared correlation coefficient of 0.994. The standard deviation 
of replicate measurements was below 5%. 
 
 
3.7.    Serum reading and practical application of the device 
Considering that the targeted biosensor was meant to operate 
well in serum, it was important to check the performance of the 
biosensor under close-to-real conditions. This was done by 
replacing the buffer solution by FCS, prepared in diluted or non- 
 
diluted (equal to biological composition) solutions. FCS was 
used to simulate serum because it displays great similarity to 
human's serum.39 SWV and EIS studies were conducted for this 
intended application. 
The EIS spectra of the immunosensor tested with oxLDL 
diluted in FCS showed clear evidence of the presence of the 
affinity between oxLDL and the mAbs (Fig. 5A). To ensure that 
FCS was not responsible for this Rct increase, a blank signal was 
measured for FCS without oxLDL (Fig. 5B). This negative control 
showed that all biological species present in FCS were unable to 
interact with the immunosensor surface. This attributed the 
device a speci c response to human oxLDL, which is mostly 
related to the speci c affinity between the mAbs and oxLDL, 
combined with the immunosensor design. 
The analytical performance of the immunosensor in FCS 
solutions was checked by calibrating the device with oxLDL 
standards prepared in FCS. Since all samples would need at 
least one dilution step prior to analysis, diluted FCS was used in 
this case. The oxLDL concentration range was set to 0.50–50 mg 
mL-1. Under these conditions, the immunosensor was able to 
detect human oxLDL from 0.50 to 18.0 mg mL-1. The slope and 
intercept values were, respectively, 62.43 (U  x  mL mg-1) and 
540.2 U, with a squared correlation coefficient of 0.9951 (typical 
spectra in Fig. 6A and B). The limit of detection was 
0.22 mg mL-1, calculated as the interception between the linear 
and non-liner parts of the calibration curve. 
The performance of the immunosensor in diluted FCS was 
also checked by SWV. The voltammograms so obtained can be 
seen in Fig. 6. In general, the assembly of the device decreased 
 
 
Fig. 5 EIS spectra of the immunosensor with FCS (A) or oxLDL diluted 
in FCS (B). 
  
 
 
Fig. 6 EIS spectra of the immunosensor assembly and oxLDL response (A) and its operation when diluted in FCS, calibrated with oxLDL ranging 
from 0.5 to 21.5 mg mL-1, and the corresponding SWV data (C and D, respectively). 
 
 
the peak current of the redox probe (Fig. 6C), which was 
consistent with the previous EIS data. The calibration in SWV 
showed  linear  responses  ranging  from  3.0  to  10.5  mg  mL-1 
(Fig. 6D), pointing to that EIS seemed to be a more suitable 
technique for analytical application. 
 
4. Conclusions 
The use of monoclonal antibodies on a biosensing platform was 
an effective approach to monitor the level of oxLDL fraction in 
the blood, a parameter of major relevance in atherosclerosis 
disease. EIS was a suitable technique to follow the affinity 
reaction between the mAbs immobilized on the screen-printed 
electrode and oxLDL. The immunosensor displayed an unusual 
speci city for the targeted analyte, being able to detect it when 
present in real serum matrices, at concentrations within phys- 
iological levels. 
Reading in real time is achieved within 20 minutes, 
including binding of the antibody to the antigen and EIS 
reading,  and  avoiding  unnecessary  use  of conjugated 
 
antibodies for detection purposes. The screen-printed electrode 
device proposed here is expected to cost less than V10, 
excluding here the price associated with the rst production of 
the mAbs, because the necessary hybridoma cells have already 
been established and these cells are able to produce antibodies 
“inde nitely”. 
The immobilization of the antibody on the screen-printed 
electrode is also a quick process, taking only a few hours, unlike 
the typical overnight incubation in the diagnostics standards. In 
addition, the Ab immobilization in ELISA does not guarantee the 
Fab region free to bind the antigen. So, to have a good grip of 
the antibody in an ELISA plate, it is necessary that the board is of 
the type “high binding plates”, but these boards are quite expen- 
sive and even so the correct antibody orientation is not guaranteed. 
In brief, compared to the gold standard protocol of ELISA, 
the proposed device provides a much faster response at a much 
lower cost, also aiming at a suitably oriented antibody binding. 
Overall, the produced device is simple, fast, cheap, and 
portable, showing great potential to improve the current diag- 
nosis of atherosclerosis in point-of-care testing. 
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